éå»1ã¶æéã«Viridian Therapeutics Incã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã17åã«åºã¥ãããŒã¿ã
仿ãVRDNã¯11ä»¶ã®ãè²·ããã0ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããVRDNã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯36.200ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2026Q2ã«çºè¡šãããEPS -1.178ã«ç¶ããVRDNã®FY2026Q3ã®EPSã¯-0.907ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD -1.18 ã§ããããViridian Therapeutics IncVRDN ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD -1.03 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD -0.91 ãšäºæ³ãããŸãã